Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD)

Q: What does CUSIP 002942100 represent in this 13F holders report?

CUSIP 002942100 is the security identifier for AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") used to aggregate holder disclosures.

Q: How many institutions held AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") in Q2 2026?

12 institutional investors reported AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") for Q2 2026. Use the holders table for investor-level position and value details.

CUSIP: 002942100

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class: Equity / Common Stock, par value $0.00001 per share (the "Shares")
Total 13F shares: 26,992
Total 13F value: $174,661
Share change: +19,471
SEC-reported price per share: $5.76
Number of holders: 12
Value change: +$135,559
Number of buys: 10
Number of sells: 3
Shares outstanding: 21,303,054

Security key

002942100

Report period

Q2 2026

Institutions

Top holders

AARD full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 Aardvark Therapeutics, Inc. SEC filings Aardvark Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 002942100

Previous quarter: Q1 2026

Recent filing periods:

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Ownership snapshot

Top reported holders of AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Decheng Capital Global Li...

Disclosed value leader

Tien-Li Lee

Comparable rows

15/15

Latest evidence

31 Mar 2026

3/4/5 13D/G 13F Lead comparable stake: 18% 13D/G row: Decheng Capital Global Life Sciences Fund IV, L.P. Showing 1-6 of 15 holder rows.

Quick read

Decheng Capital Global Life Sciences Fund IV, L.P. leads the comparable SEC ownership view at 18%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Decheng Capital Global Life Sciences Fund IV, L.P.'s linked filing trail.

Comparable ownership Top 5

Decheng Capital Global Life Scien... 18%

Tien-Li Lee 14%

Finian Tan 9.6%

CITADEL ADVISORS LLC 5.6%

Decheng Capital LLC 18%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Decheng Capital Global Life Sciences Fund IV, L.P.	3/4/5 13D/G 10%+ Owner · Xiangmin Cui 3/4/5 13D/G	18% from 13D/G	— 3,917,299 shares	—	14 Feb 2025
Tien-Li Lee	3/4/5 13D/G Chief Executive Officer, Director, 10%+ Owner 3/4/5 13D/G	14% from 13D/G	$38,483,058 3,229,492 shares mixed-class rows	+$358,673	09 Feb 2026
Finian Tan	13D/G Vickers Venture Fund VI Pte. Ltd. 13D/G	9.6%	$23,441,810 2,050,902 shares	$0	12 Feb 2025
CITADEL ADVISORS LLC	13D/G 13F Kenneth Griffin · Company 13D/G 13F	5.6%	$13,635,659 1,192,971 shares	$0	14 Feb 2025
Decheng Capital LLC	13F Company 13F	18%	$14,768,217 3,917,299 shares	—	31 Mar 2026
Laurion Capital Management LP	13F Company 13F	4.9%	$3,899,910 1,034,459 shares	—	31 Mar 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

26,992

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders

Q2 2026 holders

Holder diff

-65

Investor	Q1 2026 Shares	Q2 2026 Shares	Share Diff	Share Chg %	Q1 2026 value	Q2 2026 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend